Table 2.
Cancer specific characteristics according to AKI stage
| Total (n=3,202) | No AKI (n=1,783) | AKI stage 1 (n=1,351) | AKI stage 2/3 (n=68) | p for trend | |
|---|---|---|---|---|---|
| Pathology (%) | |||||
| Adenocarcinoma | 56.2 | 60.9 | 50.3 | 50.0 | < 0.001 |
| Squamous cell carcinoma | 23.1 | 20.0 | 27.3 | 21.4 | |
| Small cell carcinoma | 10.6 | 8.1 | 13.5 | 15.7 | |
| Others | 10.1 | 10.9 | 8.9 | 12.9 | |
| SEER stage (%) | |||||
| 0, 1 (localized or in situ) | 23.3 | 26.5 | 19.2 | 21.4 | < 0.001 |
| 2, 3, 4, 5 (regional) | 35.9 | 34.4 | 28.2 | 32.9 | |
| 7 (distant) | 27.6 | 25.6 | 30.1 | 31.4 | |
| 9 (unknown) | 13.1 | 13.5 | 12.5 | 14.3 | |
| Treatment (%) | |||||
| Surgery yes, chemotherapy no | 25.8 | 31.0 | 19.2 | 18.6 | 0.008 |
| Surgery yes, chemotherapy yes | 24.9 | 21.7 | 29.2 | 20.0 | |
| Surgery no, chemotherapy yes | 38.6 | 32.7 | 45.7 | 51.4 | |
| Surgery no, chemotherapy no | 10.8 | 14.5 | 5.9 | 10.0 | |
| Nephrotoxic chemotherapeutic agents (%) a) | 53.6 | 53.1 | 54.0 | 58.8 | 0.589 |
Values are presented as percentage. AKI, acute kidney injury; SEER, Surveillance, Epidemiology, and End Results.
a)
Nephrotoxic chemotherapeutic agents: cisplatin, carboplatin, ifosfamide, gemcitabine, pemetrexed.